Actively Recruiting
Study of Umbilical Cord Blood Platelet-Rich Plasma Therapy to Treat Thin Endometrium and Asherman Syndrome in Women Aged 18 to 48
Led by Fundación IVI · Updated on 2026-07-13
35
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the use of platelet-rich plasma PRP derived from umbilical cord blood hUC-PRP to treat women with endometrial pathologies such as Asherman syndrome, endometrial atrophy, or thin endometrium. This study seeks to confirm earlier findings that hUC-PRP may help increase endometrial thickness and improve its pattern in affected women aged 18 to 48. The trial builds on preliminary results from a smaller pilot study involving 15 patients. Participants will receive a single administration of allogeneic hUC-PRP injected into the subendometrial wall of the uterine cavity via hysteroscopy. Before this injection, patients will undergo 10 2 days of estrogen treatment. The hUC-PRP is activated with 5% calcium chloride prior to injection. The treatment phase occurs following hormone replacement therapy cycles. Throughout the study, women will be closely monitored to measure changes in endometrial thickness over 8 weeks after treatment. The main outcome is the increase in endometrial thickness compared to baseline. Safety assessments include screening for infections and viral safety tests. Participants will be assessed for eligibility and monitored during the study to evaluate the therapys effects.
CONDITIONS
Brief Title
CURENDO (Cord-blood Uterine Regeneration Endometrium): Platelet-rich Plasma Therapy Derived From Umbilical Cord Blood for the Treatment of Endometrial Pathologies (Asherman Syndrome / Endometrial Atrophy / Thin Endometrium)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here